Lambda Therapeutic Research continues to demonstrate exceptional performance in regulatory compliance, marking the successful Swissmedic inspection for Pharmacovigilance (PV) services on January 27-28, 2025. This milestone reflects Lambda’s unwavering commitment to delivering high-quality services and its “Always Inspection Ready” approach.
Lambda’s team provided comprehensive support, ensuring a seamless inspection process for the client. The inspection’s success with zero findings is a testament to Lambda’s robust operational procedures, rigorous quality controls, and commitment to maintaining the highest standards of compliance. This achievement underscores Lambda Therapeutic Research’s role as a trusted partner in pharmacovigilance and clinical research, providing reliable, high-quality services across different regulatory environments and geographies.
Lambda Therapeutic Research, a leading global Clinical Research Organization (CRO), offers comprehensive drug safety and pharmacovigilance services across all clinical and post-marketing phases. Our established PV framework guarantees thorough safety monitoring and regulatory compliance for both clinical and commercial products, providing end-to-end support throughout the entire lifecycle of medicinal products.
